Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
Status:
Not yet recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor
(VEGF), combined with fluoropyrimidine-based chemotherapy is now the standard first and
second-line treatment for metastatic colorectal cancer. The efficacy of bevacizumab with
cytotoxic agents in the third-line treatment of patients with mCRC is still unknown.